Mona Al Mukaddam, M.D., M.S.
Professor of Clinical Medicine (Endocrinology, Diabetes and Metabolism)
Department: Medicine
Contact information
3rd floor Penn Medicine University City
3737 Market Street
Philadelphia, PA 19104
3737 Market Street
Philadelphia, PA 19104
Office: 215-662-9905
Links
Webinar on COVID-19 vaccinations in FOP patients
Interviewed for a Penn primary care podcast to discuss osteoporosis
Remembering Carol Orzel, FOP patient, who donated her skeleton to the the mutter museum.
Endocrinology Spotlight Series: Management of Calcium and Metabolic Bone Disorders Expert Guidance for Challenging Cases
Commentary regarding type 1 diabetes and bone in medpage today
Interviewed by checkrare after Palovarotene was approved by the FDA and the first and only treatment for FOP.
Penn Bone Center
International Fibrodysplasia Ossificans Progressiva Association
CDC sponsored virtual grand round on evaluation and management of bone health in patients with Thalassemia https://www.cdc.gov/ncbddd/thalassemia/webinar-archives.html
Report on a patient with a rare bone disease correctly diagnosed at the Penn Bone Center
CME titled "First Do No Harm: Realizing Timely Diagnosis and Treatment for Patients with Fibrodysplasia Ossificans Progressiva"
Penn bone Center featured in Penn Medicine Women's health newsletter
Official website for International Clinical Council on Fibrodysplasia Ossificans Progressiva
Penn Primary Care Podcast discussing osteoporosis Hosted by Drs Amber Bird, Deepa Rani Nandiwada and Mona Al Mukaddam
Podcast on Women's Health in FOP
Global CME on treatment considerations in Fibrodysplasia Ossificans Progressiva (FOP)
Webinar for BMT organization on "Bone Health after Transplant"
Webinar on COVID-19 vaccinations in FOP patients
Interviewed for a Penn primary care podcast to discuss osteoporosis
Remembering Carol Orzel, FOP patient, who donated her skeleton to the the mutter museum.
Endocrinology Spotlight Series: Management of Calcium and Metabolic Bone Disorders Expert Guidance for Challenging Cases
Commentary regarding type 1 diabetes and bone in medpage today
Interviewed by checkrare after Palovarotene was approved by the FDA and the first and only treatment for FOP.
Penn Bone Center
International Fibrodysplasia Ossificans Progressiva Association
CDC sponsored virtual grand round on evaluation and management of bone health in patients with Thalassemia https://www.cdc.gov/ncbddd/thalassemia/webinar-archives.html
Report on a patient with a rare bone disease correctly diagnosed at the Penn Bone Center
CME titled "First Do No Harm: Realizing Timely Diagnosis and Treatment for Patients with Fibrodysplasia Ossificans Progressiva"
Penn bone Center featured in Penn Medicine Women's health newsletter
Official website for International Clinical Council on Fibrodysplasia Ossificans Progressiva
Penn Primary Care Podcast discussing osteoporosis Hosted by Drs Amber Bird, Deepa Rani Nandiwada and Mona Al Mukaddam
Podcast on Women's Health in FOP
Global CME on treatment considerations in Fibrodysplasia Ossificans Progressiva (FOP)
Webinar for BMT organization on "Bone Health after Transplant"
Education:
BS
American University of Beirut, Lebanon, 2001.
MD
American University of Beirut, Lebanon, 2005.
MS
University of Pennsylvania, Institute of Translational Medicine and Therapeutics, 2013.
Permanent linkBS
American University of Beirut, Lebanon, 2001.
MD
American University of Beirut, Lebanon, 2005.
MS
University of Pennsylvania, Institute of Translational Medicine and Therapeutics, 2013.
Description of Clinical Expertise
Rare bone disease with expertise in Fibrodysplasia Ossificans Progressiva and hypophosphatasia. Metabolic bone and calcium disorders including osteoporosis, Paget's disease, hypo- and hyper-parathyroidism as well as bone diseases related to transplant, medications (example aromatase inhibitors and glucocorticoids) and iron overload.Description of Research Expertise
Clinical research in Fibrodysplasia Ossificans Progressiva and hypophosphatasia.Evaluation of osteoporosis and the effects of treatment/diseases on "bone quality" using high resolution imaging of bone (uMRI).
Selected Publications
Cassandra Crompton, PharmD; Kassidy Baum, PharmD; Michael Silvey, PharmD; Mona Al Mukaddam, MD, MS: Comparison of Forteo® and Teriparatide on Improvements in Bone Mineral Density Poster Presentation at Endocrine Society Annual Meeting July 2025.Javier Ocampo Mascaro, Katherine Toder, Staci Kallish, Mona Al Mukaddam : Applying the Hypophosphatasia Diagnostic Criteria in a Patient Cohort at the Penn Bone Center Post Presentation at Endocrine Society Annual Meeting July 2025.
Bassam AlHamer and Mona Al Mukaddam : Silicosis Induced Hypercalcemia Treated with Ketoconazole Post Presentation at Endocrine Society Annual Meeting July 2025.
Natalie Dapas, Mona Al Mukaddam, Hamdee Attallah, Carrie M. Burns, Robert Jones, Julia Kharlip, Kristen Noelle Kobaly, Serena Cardillo: Creation of Educational Resources to Improve Endocrine Fellow Outpatient Curriculum. Poster Presentation at Endocrine Society Annual Meeting July 2025.
Vincent A. Verheij, Robert J. Diecidue, Esmée Botman, Joseph D. Harrington, Nobuhiko Haga, Alberto Hidalgo-Bravo, Patricia L. R. Delai, Vrisha Madhuri, Mona Al Mukaddam, Keqin Zhang, Tae-Joon Cho, Rolf Morhart, Richard Keen, Carmen L. De Cunto, Clive S. Friedman, Zvi Grunwald, Michael Zasloff, J. Coen Netelenbos, Edward Hsiao, Frederick S. Kaplan, Robert J. Pignolo, Christiaan Scott and Elisabeth Marelise W. Eekhoff: Palovarotene in fibrodysplasia ossificans progressiva: review and perspective Expert Opinion on Pharmacotherapy January 2025 Notes: https://doi.org/10.1080/14656566.2025.2452938.
Edward C. Hsia, Robert J. Pignolo, Mona Al Mukaddam, Geneviève Baujat, Staffan K. Berglund, Angela M. Cheung, Carmen De Cunto, Patricia Delai, Peter Kannu, Richard Keen, Edna E. Mancilla, Fei Shih, Andrew Strahs and Frederick S. Kaplan: The Impact of Palovarotene Treatment on Heterotopic Ossification in Patients with Fibrodysplasia Ossificans Progressiva With and Without Flare-Ups: Data from the Phase III MOVE Trial and Natural History Study. Poster presentation ASBMR annual meeting, Toronto, CA Sept 2024 Notes: Poster.
Tarun Mattikalli, Rashad Madi, Steven Graham, Julio Ojea Quintana, Hannah Rosenblatt, Bruce J. Kneeland, Amna Nabeel Khan, Benjamin T. Newman, Elena Taratuta, Mona Al Mukaddam, Chamith S. Rajapakse: Using Machine Learning Algorithms for High-Risk Patient Identification in Atypical Femoral Fractures. Poster presentation ASBMR annual meeting, Toronto, CA Sept 2024 Notes: Poster.
Keen R, Dahir KM, McGinniss J, Sanchez RJ, Mellis S, Economides AN, Di Rocco M, Orcel P, Roux C, Tabarkiewicz J, Bachiller-Corral J, Cheung AM, Al Mukaddam M, Mohammadi K, Gu J, Srinivasan D, Trotter DG, Eekhoff EMW, Kaplan FS, Pignolo RJ.: Characterization of flare-ups and impact of Garetosmab in adults with Fibrodysplasia Ossificans Progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial. J Bone Miner Res 26(39): 1486-1492, Aug 2024 Notes: doi: 10.1093/jbmr/zjae140.
Patricia Delai, Mona Al Mukaddam, Geneviève Baujat, Carmen De Cunto, Edward C. Hsiao, Richard Keen, Kim Croskery, Jean-Luc Delhay, Christelle Pommie, Robert J. Pignolo: Incidence and management of skin adverse events in patients receiving palovarotene for the treatment of fibrodysplasia ossificans progressiva. Poster Presentation at ICCBH Salzburg, Austria June 2024.
Edna E. Mancilla, Geneviève Baujat, Mona Al Mukaddam, Javier Bachiller-Corral, Staffan K. Berglund, Carmen De Cunto, Patricia Delai, Richard Keen, Riccardo Papa, Robert J. Pignolo, Sally Lanar, Alexia Marrel, Alexander Artyomenko, Kim Croskery, Christelle Pommie, Edward C. Hsiao: The impact of palovarotene on patients with fibrodysplasia ossificans progressiva: Results from participant interviews in the phase III PIVOINE trial. Oral Presentation at ICCBH Salzburg, Austria June 2024.